Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

COGT

Cogent Biosciences Inc

Nov 17 • 01:44PM ET

34.38

+0.84 2.50 %

Healthcare • Biotechnology • USA • NASD

Peers: BLUE VRTX BEAM CRSP BPMC NTLA GILD EDIT ALLO FATE

| Held by: IWM XBI VTI IWO IBB SCHA VXF IWC VTWO LFSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.37	Insider Own	19.43%	Shs Outstand	139.83M	Perf Week	5.91%
Market Cap	5.23B	Forward P/E	-	EPS next Y	-1.79	Insider Trans	10.38%	Shs Float	121.57M	Perf Month	109.76%
Enterprise Value	5.01B	PEG	-	EPS next Q	-0.52	Inst Own	93.12%	Short Float	12.38%	Perf Quarter	192.35%
Income	-281.86M	P/S	-	EPS this Y	8.36%	Inst Trans	10.79%	Short Ratio	5.62	Perf Half Y	590.36%
Sales	0.00M	P/B	24.71	EPS next Y	20.59%	ROA	-72.69%	Short Interest	15.05M	Perf YTD	340.77%
Book/sh	1.39	P/C	13.37	EPS next 5Y	43.19%	ROE	-95.40%	52W High	36.29 -5.26%	Perf Year	230.58%
Cash/sh	2.57	P/FCF	-	EPS past 3/5Y	-9.70% 10.02%	ROIC	-78.01%	52W Low	3.72 824.19%	Perf 3Y	170.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.81% 8.09%	Perf 5Y	210.01%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	4.32%	Oper. Margin	-	ATR (14)	2.69	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.38	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	83.21	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	6.38	EPS Q/Q	8.23%	SMA20	64.51%	Beta	0.39	Target Price	47.27
Payout	-	Debt/Eq	0.20	Sales Q/Q	-	SMA50	102.99%	Rel Volume	0.99	Prev Close	33.54
Employees	205	LT Debt/Eq	0.19	Earnings	Nov 03 BMO	SMA200	236.22%	Avg Volume	2.68M	Price	34.38
IPO	Mar 29, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-4.38% -	Trades		Volume	1,772,668	Change	2.50%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-10-25	Upgrade	Wedbush	Neutral → Outperform	$38
Nov-10-25	Upgrade	Stifel	Hold → Buy	$40
Oct-16-25	Initiated	Stifel	Hold	$16
Sep-03-25	Initiated	Raymond James	Strong Buy	$30
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$17
Dec-11-24	Downgrade	Needham	Buy → Hold
Feb-26-24	Downgrade	Robert W. Baird	Outperform → Neutral	$14 → $8
Feb-08-24	Initiated	Citigroup	Buy	$11
Dec-11-23	Downgrade	Wedbush	Outperform → Neutral	$5
Dec-08-23	Initiated	JP Morgan	Overweight	$18
Apr-28-23	Initiated	Robert W. Baird	Outperform	$20
Mar-27-23	Resumed	H.C. Wainwright	Buy	$28
Dec-14-22	Initiated	Needham	Buy	$24
Jun-28-22	Initiated	Guggenheim	Buy	$15
Oct-11-21	Initiated	H.C. Wainwright	Buy	$25
Jun-09-21	Resumed	Jefferies	Buy	$20
Dec-23-20	Initiated	Piper Sandler	Overweight	$22
Oct-14-20	Initiated	Ladenburg Thalmann	Buy	$4

Show Previous Ratings

Nov-16-25 11:16AM	Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress (Insider Monkey)
Nov-14-25 08:00AM	Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire)
Nov-12-25 05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive) +5.51%
Nov-11-25 11:16PM	Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 (GlobeNewswire)
12:49PM	Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial (Insider Monkey)
04:01PM	Loading…
Nov-10-25 04:01PM	Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock (GlobeNewswire) +119.03%
01:48PM	Cogent Biosciences Stock Surges 136%. Investors See Promise in Its Cancer Drug. (Barrons.com)
10:45AM	Cogent Biosciences Stock Surges 127%. Why Investors See Promise in Its Cancer Drug. (Barrons.com)
10:43AM	Cogent Biosciences Hits 7-Year High, Up 120% On Its New Stomach Cancer Promise (Investor's Business Daily)
07:00AM	Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
06:14AM	Stock Market Today: Nasdaq, S&P 500, Russell Jump Over 1% As Tech Rebound, Government Reopening Infuses Optimism into Markets (TheStreet)
Nov-03-25 09:01AM	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results (GlobeNewswire)
09:00AM	Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting (GlobeNewswire)
Oct-24-25 12:30PM	Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-20-25 08:32AM	Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib (GlobeNewswire)
04:05PM	Loading…
Sep-29-25 04:05PM	Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-25 12:59PM	Cogent, Dime added to Raymond James analyst favorites list (Investing.com)
Aug-26-25 08:00AM	Cogent Biosciences Announces Participation in the Citi Biopharma Conference (GlobeNewswire)
Aug-05-25 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results (GlobeNewswire) -5.73%
Jul-31-25 05:31PM	KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 \| DelveInsight (PR Newswire)
Jul-24-25 11:47PM	Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline (Insider Monkey)
Jul-18-25 06:19PM	Rocket, TaskUS, Appian, and More Stocks See Action From Activist Investors (Barrons.com)
Jul-16-25 12:23PM	Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating (Insider Monkey)
Jul-10-25 04:01PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jul-08-25 09:36PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock (GlobeNewswire) +6.34%
04:26PM	Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock (GlobeNewswire)
10:54AM	COGT Stock Soars on Phase III Systemic Mastocytosis Study Success (Zacks)
Jul-07-25 07:06AM	Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis (GlobeNewswire) +23.35%
Jun-11-25 08:00AM	Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing (GlobeNewswire)
May-29-25 08:00AM	Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire) +12.91%
09:55AM	Loading…
May-13-25 09:55AM	Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade (Zacks)
08:50AM	Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now (Insider Monkey)
May-06-25 08:00AM	Cogent Biosciences Reports First Quarter 2025 Financial Results (GlobeNewswire) -15.62%
May-05-25 07:57AM	Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential? (Insider Monkey) -5.11%
Apr-25-25 08:08AM	Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders (GlobeNewswire)
Apr-20-25 06:16AM	Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts (Insider Monkey)
Apr-16-25 10:03AM	Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -12.32%
Apr-09-25 04:28PM	Cogent: Several 2025 Readouts On Deck With Bezuclastinib Advancement (Seeking Alpha) +7.73% -9.87%
Mar-25-25 04:31PM	Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -6.76% -6.23%
Mar-20-25 08:32AM	Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? (Zacks)
Mar-07-25 08:00AM	Cogent Biosciences Announces Participation in the Leerink Healthcare Conference (GlobeNewswire) -5.40%
Feb-27-25 08:00AM	Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients (GlobeNewswire)
Feb-25-25 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -6.30%
Feb-10-25 09:15AM	Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting (GlobeNewswire)
Jan-30-25 08:00AM	Cogent Biosciences to Participate in the Guggenheim Biotech Conference (GlobeNewswire)
Jan-13-25 08:00AM	Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics (GlobeNewswire)
Jan-08-25 08:00AM	Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 07:00AM	Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients (GlobeNewswire) +8.77%
Dec-08-24 12:00PM	Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Nov-05-24 09:00AM	Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting (GlobeNewswire) -15.84%
Oct-23-24 07:00AM	Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-09-24 08:03AM	Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target (Insider Monkey)
Sep-03-24 08:00AM	Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis (GlobeNewswire)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-06-24 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-28-24 09:18AM	Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting (Zacks)
Jun-27-24 08:00AM	Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial (GlobeNewswire)
Jun-14-24 07:30AM	Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) (GlobeNewswire) -6.18%
May-23-24 05:05PM	Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer (GlobeNewswire) -6.72% +9.75%
05:01PM	Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting (GlobeNewswire)
May-07-24 01:52PM	COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Cogent Biosciences Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-09-24 09:00AM	Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor (GlobeNewswire) +7.21%
Mar-13-24 07:06AM	5 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Feb-28-24 04:32AM	COGT Reports Full Year 2023 Financial Results and Business Highlights (GuruFocus.com)
Feb-26-24 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-22-24 02:30PM	Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (GlobeNewswire)
Feb-14-24 07:00AM	Cogent Biosciences Announces Oversubscribed $225 Million Private Placement (GlobeNewswire) +59.34%
Feb-05-24 09:00AM	Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting (GlobeNewswire) +18.75%
Jan-09-24 08:00AM	Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics (GlobeNewswire) -7.73%
Jan-02-24 08:00AM	Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.12%
Dec-11-23 07:55AM	Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire) -53.01%
Dec-09-23 01:30PM	Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) (GlobeNewswire)
Dec-07-23 09:00AM	Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3K inhibitor programs at the San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-04-23 08:00AM	Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-29-23 08:00AM	Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium (GlobeNewswire) +5.67%
Nov-02-23 09:00AM	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-14-23 12:30PM	Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Aug-13-23 08:51AM	After losing 15% in the past year, Cogent Biosciences, Inc. (NASDAQ:COGT) institutional owners must be relieved by the recent gain (Simply Wall St.)
Aug-08-23 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results (GlobeNewswire) +7.62%
Jul-10-23 07:35PM	Analysts Say These 2 Stocks Are Their Top Picks for the Rest of 2023 (TipRanks)
Jun-09-23 04:01PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock (GlobeNewswire)
Jun-07-23 09:00AM	Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference (GlobeNewswire) -10.21%
Jun-06-23 08:25PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock (GlobeNewswire)
04:05PM	Cogent Biosciences Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-03-23 02:15PM	Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
May-23-23 08:00AM	Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
May-09-23 08:00AM	Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-17-23 09:00AM	Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis (GlobeNewswire) +6.62%
Apr-12-23 08:00AM	Cogent Biosciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire) -5.74%
Mar-14-23 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +7.54%
Feb-01-23 08:00AM	Cogent Biosciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Jan-11-23 11:03AM	Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-09-23 08:00AM	Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics (GlobeNewswire)
Jan-05-23 08:00AM	Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-22 05:30PM	Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Dec-05-22 08:00AM	Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (GlobeNewswire)
Nov-28-22 04:15PM	Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development (GlobeNewswire) +6.14%
Nov-14-22 07:00AM	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-09-22 08:00AM	Cogent Biosciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire) -5.63%

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairmount Funds Management LLC	Director	Jul 10 '25	Buy	9.00	2,777,777	24,999,993	9,003,418	Jul 14 04:30 PM
Pinnow Cole	Chief Commercial Officer	Jan 14 '25	Buy	7.60	43,750	332,412	45,848	Jan 15 07:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COGT

Cogent Biosciences Inc

Upgrade your FINVIZ experience